Immunotherapy of Genitourinary Malignancies
Authors:
Open Access
- 5 March 2012
- journal article
- review article
- Published by Hindawi Limited in Journal of Oncology
- Vol. 2012, 1-8
Abstract
Most cancer patients are treated with some combination of surgery, radiation, and chemotherapy. Despite recent advances in local therapy with curative intent, chemotherapeutic treatments for metastatic disease often remain unsatisfying due to severe side effects and incomplete long-term remission. Therefore, the evaluation of novel therapeutic options is of great interest. Conventional, along with newer treatment strategies target the immune system that suppresses genitourinary (GU) malignancies. Metastatic renal cell carcinoma and non-muscle-invasive bladder caner represent the most immune-responsive types of all human cancer. This review examines the rationale and emerging evidence supporting the anticancer activity of immunotherapy, against GU malignancies.Keywords
This publication has 65 references indexed in Scilit:
- Cancer Patients Treated with Sunitinib or Sorafenib Have Sufficient Antibody and Cellular Immune Responses to Warrant Influenza VaccinationClinical Cancer Research, 2011
- EAU Guidelines on Non–Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 UpdateEuropean Urology, 2011
- Cancer immunotherapy: Progress and challenges in the clinical settingEuropean Journal of Immunology, 2011
- A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinomaAnnals of Oncology, 2011
- Phase I/II trial of subcutaneous interleukin‐2, granulocyte‐macrophage colony‐stimulating factor and interferon‐α in patients with metastatic renal cell carcinomaBJU International, 2011
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Retrospective Analysis of the Safety and Efficacy of Interleukin-2 After Prior VEGF-targeted Therapy in Patients With Advanced Renal Cell CarcinomaJournal of Immunotherapy, 2009
- Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer modelJournal of Experimental & Clinical Cancer Research, 2008
- Leptin ResistanceJACC, 2008
- Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammationBritish Journal of Dermatology, 2008